136 related articles for article (PubMed ID: 35647403)
1. The Prognostic Role of Plasma Epstein-Barr Virus DNA Levels in the Middle of Intensity Modulated Radiation Therapy to Guide Cisplatin Dose Recommendation in Concurrent Chemoradiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma: A Large Cohort Study.
Yang ZC; Du CC; Liu LT; Liang YJ; Tang LQ; Chen QY; Mai HQ; Guo SS
Adv Radiat Oncol; 2022; 7(3):100908. PubMed ID: 35647403
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
[TBL] [Abstract][Full Text] [Related]
3. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
4. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
5. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma.
Prayongrat A; Chakkabat C; Kannarunimit D; Hansasuta P; Lertbutsayanukul C
J Radiat Res; 2017 Jul; 58(4):509-516. PubMed ID: 28204596
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y
Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828
[TBL] [Abstract][Full Text] [Related]
9. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
11. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
[TBL] [Abstract][Full Text] [Related]
12. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
[TBL] [Abstract][Full Text] [Related]
13. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
[No Abstract] [Full Text] [Related]
14. Optimal plasma pretreatment EBV DNA cut-off point for nasopharyngeal cancer patients treated with intensity modulated radiation therapy.
Lertbutsayanukul C; Kannarunimit D; Netsawang B; Kitpanit S; Chakkabat C; Hansasuta P; Prayongrat A
Jpn J Clin Oncol; 2018 May; 48(5):467-475. PubMed ID: 29522203
[TBL] [Abstract][Full Text] [Related]
15. Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases.
Ou X; Xu T; He X; Ying H; Hu C
J Cancer; 2017; 8(14):2836-2845. PubMed ID: 28928873
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Plasma Epstein-Barr Virus DNA in Children and Adolescent Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy.
Qiu W; Lv X; Guo X; Yuan Y
Front Oncol; 2020; 10():356. PubMed ID: 32296633
[No Abstract] [Full Text] [Related]
17. Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma.
Zhu L; Ouyang T; Xiong Y; Ba L; Li Q; Qiu M; Zou Z; Peng G
Front Oncol; 2021; 11():714433. PubMed ID: 34707987
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
19. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on plasma Epstein-Barr virus DNA level after induction chemotherapy.
Liu SL; Sun XS; Liu LT; Sun R; Luo DH; Chen QY; Lin HX; Yuan L; Tang LQ; Guo L; Mai HQ
Aging (Albany NY); 2020 Mar; 12(6):4931-4944. PubMed ID: 32221045
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Plasma EBV DNA for Nasopharyngeal Cancer Patients during Treatment with Intensity-modulated Radiation Therapy and Concurrent Chemotherapy.
Lertbutsayanukul C; Kannarunimit D; Prayongrat A; Chakkabat C; Kitpanit S; Hansasuta P
Radiol Oncol; 2018 Jun; 52(2):195-203. PubMed ID: 30018524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
